Advanced search    

Search: authors:"J. Albanell"

14 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone...

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

urothelial cancer ''unfit'' for cisplatin-based chemotherapy: phase II-results of EORTC study 30986 . J Clin Oncol 2009 ; 27 : 5634 - 5639 . 8. Bellmunt J , Albanell J , Gallego OS et al. Carboplatin

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Background Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully characterized. This study investigates the value of CT and hormone therapy (HT) in luminal breast cancer patients in the neoadjuvant setting.

Mechanism of action of anti-HER2 monoclonal antibodies

extracellular domain in predicting response to chemotherapy in breast cancer patients . Proc Am Soc Clin Oncol 1996 ; 15 : 108 (Abstr 96). 52. Codony-Servat J , Albanell J , Lopez-Talavera JC et al. Cleavage of ... on breast cancer cells in vitro . Int J Cancer 1997 ; 73 : 875 - 9 . 57. Codony J , Albanell J , Arribas J , Baselga J . Regulated shedding of the HER2 receptor ectodomain in human breast cancer cells

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

Background: Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized.

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

Background: The additive cytotoxicity in vitro prompted a clinical study evaluating the non-prodrug rapamycin analogue ridaforolimus (AP23573; MK-8669; formerly deforolimus) administered i.v. combined with paclitaxel (PTX; Taxol). Materials and methods: Patients with taxane-sensitive solid tumors were eligible. The main dose escalation foresaw 50% ridaforolimus increments from 25...

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

J. Albanell 6 7 8 A. Gonza lez 13 M. Ruiz-Borrego 12 E. Alba 11 J. A. Garca-Saenz 10 J. M. Corominas 6 7 15 O. Burgues 14 V. Furio 9 A. Rojo 4 J. Palacios 5 B. Bermejo 2 M. Martnez-Garca 7 8 M. L

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

ScholarSearch for J Albanell in:Nature Research journals • PubMed • Google Scholar Corresponding author Correspondence to C Montagut. Rights and permissions From twelve months after its original publication

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

Background: Up to 50% of patients with bladder cancer cannot be treated with cisplatin because they are considered unfit due to poor renal function. Gemcitabine and oxaliplatin are active, nonnephrotoxic therapies with nonoverlapping toxicity profiles that provide an alternative therapy for this group of patients. Patients and methods: In a multicenter study, patients received...

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

Background: A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Patients and methods: Eighty-three patients with histologically proven metastatic breast cancer were randomised to receive either docetaxel 40 mg/m2 weekly for 6 consecutive weeks followed by 2 weeks without...

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group

Background: The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast cancer. Patients and methods: Over a 4-year period, 985 women undergoing curative surgery for breast cancer (T1–3 N0–2 M0, stage I–IIIA...